Actinogen Medical Limited (FRA:3AC)
Germany · Delayed Price · Currency is EUR 0.0365
+0.0050 (15.87%)
At close: Dec 1, 2025
Actinogen Medical Company Description
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases.
The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Actinogen Medical Limited
| Country | Australia |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 6 |
| CEO | Steven Gourlay |
Contact Details
Address: 109 Pitt Street Sydney, 2000 Australia | |
| Phone | 61 2 8964 7401 |
| Website | actinogen.com.au |
Stock Details
| Ticker Symbol | 3AC |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Steven Gourlay | Chief Executive Officer |
| William Souter | Chief Financial Officer |
| Michael Roberts | Head of Investor Relations |